Key takeaways
- 400-600 total estimated GCC Pompe disease prevalence, consanguinity-elevated, diagnosed and undiagnosed combined
- 1:20,000-35,000 GCC Pompe incidence vs a global rate of roughly 1:40,000-57,000, elevated by consanguinity
- 200-300 GCC patients actively managed on enzyme replacement therapy, the broader treated-population figure
- 80-120 long-term-stable patients within NPHC's tracked annual Pompe ERT budget, a narrower core inside the actively-managed population
GCC Pompe sizing has three layers, not three contradictions: 400-600 total prevalence, 200-300 actively managed on ERT, and an 80-120 long-term-stable core inside NPHC's tracked formulary budget.
GCC Pompe disease incidence runs 1 in 20,000 to 35,000 live births, elevated above the global rate of roughly 1 in 40,000 to 57,000 by the region's consanguinity pattern, yielding an estimated 400 to 600 total GCC patients across all six states. That figure includes both diagnosed and undiagnosed cases; consistent with the broader GCC diagnostic-delay pattern, a meaningful share remains undetected, particularly late-onset patients still working through a limb-girdle-muscular-dystrophy diagnostic detour before GAA confirmation. Of the 400-600 total, an estimated 200 to 300 patients are actively managed on enzyme replacement therapy across the region's metabolic disease centres, the broader treated population a launch plan should reference for total addressable reach.
NPHC's own formulary budget, by contrast, tracks a narrower core: an estimated 80 to 120 patients receiving continuous, budget-tracked ERT under NPHC's annual SAR 100-160 million Pompe programme. This is not a fourth, contradictory figure; it most likely reflects the long-term-stable subset of the 200-300 actively-managed population, those with an established treatment history and confirmed NPHC coverage, rather than every patient currently receiving ERT through any channel, including newly diagnosed infantile-onset cases still stabilizing on therapy. A new entrant should size its near-term commercial opportunity against the 200-300 actively-managed figure, and its NPHC budget-negotiation baseline against the narrower 80-120 core NPHC already tracks.
GCC Pompe sizing — prevalence, actively-managed cohort, and NPHC-tracked core compared
| Sizing Layer | Population Estimate | Source |
|---|---|---|
| Total prevalence (consanguinity-elevated) | 400-600 patients | GCC genetics and rare disease society Pompe case registry; Saudi consanguinity Pompe data |
| Actively managed on ERT | 200-300 patients | GCC metabolic disease network registry |
| NPHC budget-tracked core (long-term-stable) | 80-120 patients | NPHC Pompe disease programme guidelines 2023 |
| Estimated undiagnosed / delayed-diagnosis share | Balance of the 400-600 total not yet actively managed | Derived from prevalence-vs-actively-managed gap |
Sources: GCC genetics and rare disease society Pompe case registry; Saudi consanguinity Pompe prevalence data; GCC metabolic disease network registry; NPHC Pompe disease programme guidelines 2023; Al-Hassnan ZN et al. Clin Genet 2012.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Why do GCC Pompe patient counts range from 80-120 to 400-600 across sources, and how do the layers relate? • The three-layer sizing structure (400-600 total prevalence, 200-300 actively managed, 80-120 NPHC-tracked core) • why these are non-contradictory population layers, not competing estimates
- Which figure should a new entrant use for near-term commercial sizing versus NPHC budget negotiation? • The 200-300 actively-managed figure as the commercial-reach baseline • the narrower 80-120 NPHC-tracked core as the budget-negotiation baseline • why conflating them misprices either conversation
- How much of the prevalence gap is diagnostic delay versus true undiagnosed disease? • Sensitivity ranking of every sizing input • why diagnostic-delay-driven undercounting (the limb-girdle-muscular-dystrophy detour) outranks raw incidence rate as the binding assumption
What's inside
-
1 · The Binding Constraint 2 pp
- Why diagnostic delay, not incidence rate, is the assumption that determines whether the 400-600 prevalence total holds up
- Pressure-tested against the three-layer sizing gap before the rest of the model is built out
-
2 · Prevalence-Based Sizing 3 pp
- Consanguinity-elevated GCC incidence (1:20,000-35,000) and the 400-600 total prevalence estimate it implies
- Comparator against the global incidence rate
-
3 · Actively-Managed Treated-Cohort Sizing 3 pp
- The 200-300 patient actively-managed ERT population across GCC metabolic centres
- Cross-check against the prevalence-based estimate
-
4 · NPHC Budget-Tracked Core Segmentation 3 pp
- The narrower 80-120 patient long-term-stable core inside NPHC's annual budget
- Why this is a subset of, not a contradiction to, the 200-300 actively-managed figure
-
5 · Sensitivity Analysis 3 pp
- Diagnostic-delay-driven undercounting ranked above incidence rate as the binding assumption
- Scenario ranges tied to newborn-screening expansion and diagnostic-capacity growth
-
6 · Editable Excel Model —
- The full triangulated model, re-runnable with your own assumptions
-
7 · Client Alignment Questions 2 pp
- The open sizing questions your team must close before the number is used in planning
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers Pompe disease market sizing models built for forecasting and strategy teams sizing the GCC LOPD opportunity. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, market, and cohort definition.
- 2. Scoping callAXLRx analyst confirms triangulation methods and comparator set before building.
- 3. DeliveryResearch-verified sizing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx market sizing model triangulates at least two independent methods, prevalence-based and treated-cohort-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Patient Flow or forecasting model (dynamic revenue/uptake).
Pompe GCC sizing sources: GCC genetics and rare disease society Pompe case registry, Saudi consanguinity Pompe prevalence data, the GCC metabolic disease network registry, NPHC Pompe disease programme guidelines 2023, and Al-Hassnan ZN et al. Clin Genet 2012.
- Total prevalence and consanguinity-elevated incidence verified against Saudi consanguinity Pompe prevalence data and Al-Hassnan ZN et al. Clin Genet 2012
- Actively-managed treated-cohort count verified against the GCC metabolic disease network registry
- NPHC budget-tracked core verified against NPHC Pompe disease programme guidelines 2023
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Market Sizing Model includes an editable 5-sheet Excel model (Cover, Model, Research Validation, QC, Sensitivity) and a PDF methodology brief. No PowerPoint deck ships with this model type, since it is built to be worked in directly, not presented from. An optional 45-minute analyst readout call is included.
Sources How is the patient count verified?
AXLRx triangulates every GCC sizing estimate across at least two independent methods, a consanguinity-adjusted prevalence build and the regional metabolic-network and society registry counts, before it ships. Where the two disagree, both are presented with their definitional scope rather than collapsed into one number.
Customisation Can I size a specific GCC state or subpopulation?
Yes. The intake form captures your indication, target market, and cohort definition. A scoping call confirms scope before research starts. Commission via the intake form to start.